The Innovative Drugs Concept is generally rising, INNOVENT BIO (01801) increased by 7%. Institutions indicate that the actual geopolitical risks in the Sector are relatively low.

Jinwu Financial News | The Innovative Drugs sector generally rose, with Hutchmed (China) (00013) up by 3.92%. The company will announce data at the American Association for Cancer Research (AACR) 2025 annual meeting. In addition, AKESO (09926) rose by 7.1%, INNOVENT BIO (01801) rose by 7%, SKB BIO-B (06990) rose by 4.76%, KEYMED BIO-B (02162) rose by 3.41%, and 3SBIO (01530) rose by 3.28%. Sinolink's Research Reports stated that the rapidly changing external tariff environment provides the pharmaceutical sector with good anti-risk capabilities and growth potential.

Jinwu Financial NewsApr 23 22:01 ET

[Brokerage Focus] Sinolink: The actual geopolitical risk in the Innovative Drugs Sector is low. In the second half of the year, it is recommended to focus on left-side reversals.

Jinwu Finance | Sinolink's Research Reports indicate that the external tariff environment is changing rapidly, and the pharmaceutical Sector has good risk resistance and growth potential. The geopolitical risk in the Innovative Drugs Sector is very low, and there are opportunities for domestic substitution in Blood Products, Medical Device, and instruments. A reversal in the left-side Sector is imminent after the first quarter report, and attention is recommended. The firm states that in the second half of the year, attention should be given to the left-side reversal, as performance gradually recovers and the fundamentals improve. Focus on the individual stocks in Generic Drugs, chain pharmacies, Medical Device, and Traditional Chinese Medicine that are experiencing difficulties. Throughout the year, it is advised to continuously focus on the main line of Innovative Drugs and semi-Innovative Drugs; additionally, in the short term, attention should be paid to the fluctuations in tariffs regarding Blood Product

Jinwu Financial NewsApr 22 21:07 ET

SKB Biopharmaceutical Gets US FDA Clinical Trial Clearance for Anti-Tumor Drug; Shares Jump 6%

MT NewswiresApr 22 00:27 ET

Guosen: Focus on the Innovative Drugs that are accelerating their overseas expansion and the service Sector supported by policies.

Guosen recommends paying attention to the Medical Services Sector.

Zhitong FinanceApr 21 23:00 ET

Express News | Kelun-Biotech's Novel ADC Drug Skb518 Has Been Granted the Clearance of Ind From the United States Food and Drug Administration (FDA)

ReutersApr 21 08:01 ET

SKB BIO-B (06990): The innovative ADC drug SKB518's new drug clinical trial application has been approved by the USA Food and Drug Administration.

SKB BIO-B (06990) announced that the company has obtained authorization from the USA Food and Drug Administration (FDA)...

Zhitong FinanceApr 21 06:25 ET